Obesity drug developer Orexigen Therapeutics Inc. said Tuesday the U.S. Patent and Trademark Office issued a patent US7375111 with broad claims covering sustained release (SR) compositions of Bupropion and Naltrexone combined in a single dosage form. These two drugs are the active constituents in Contrave, the company's lead obesity product candidate, now in Phase III clinical trials.
Orexigen anticipates results from the first Contrave late-stage trial late this year or early next year, with USFDA filing in late 2009.
The company has another obesity candidate, Empatic, currently in mid-stage trials. It is a combination of bupropion and zonisamide, which is used to treat seizures
Orexigen anticipates results from the first Contrave late-stage trial late this year or early next year, with USFDA filing in late 2009.
The company has another obesity candidate, Empatic, currently in mid-stage trials. It is a combination of bupropion and zonisamide, which is used to treat seizures
